- Home
- REFI vs ABOS Comparison
REFI vs ABOS Comparison
Compare REFI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | ABOS |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.1M | 197.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REFI | ABOS |
|---|---|---|
| Price | $10.68 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 165.2K | ★ 340.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $17.47 | N/A |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | $18.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $1.21 |
| 52 Week High | $14.57 | $3.60 |
Technical Indicators
Market Signals| Indicator | REFI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 61.79 |
| Support Level | $10.65 | $2.13 |
| Resistance Level | $10.93 | $3.02 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 74.70 | 58.75 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.